Maxime Dely: What if We Could Leukoreduce Without a Filter?
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared on LinkedIn:
”What if we could leukoreduce without a filter?
When we talk about leukoreduction, we immediately think of leukocyte filters — disposable devices able to remove over 99% of white blood cells.
But… not everyone has access to them.
In some countries, the cost of this technology remains a major barrier to transfusion safety.
Yet there’s a simple, effective, and affordable alternative: the hard spin.
In many developing countries, the first step in whole blood processing is a soft spin.
This yields two main components:
- a PRP (platelet-rich plasma),
- and an RCC (red cell concentrate).
The issue? Around 90% of the residual white blood cells end up in the RCC.
And these cells can cause febrile non-haemolytic transfusion reactions, allergic reactions, and can even impair red cell storage quality.
By performing a hard spin, we create an interface between plasma and red cells — the well-known buffy coat.
That’s where most white cells accumulate.
The result?
A significant reduction in the residual leukocytes within the red cell concentrate — sometimes divided by 2, from 90% to 50% or even lower, depending on the separation and centrifugation settings.
The hard spin isn’t a miracle solution, but it’s a crucial first step toward safer transfusion, especially where resources are limited.
Because sometimes, innovation simply means doing better with what we have.”
Stay updated with Hemostasis Today.
-
Nov 9, 2026, 10:32Natalie Arnold: The Lp(a) Puzzle – Why Lower Levels May Not Tell the Whole Story
-
Nov 9, 2026, 10:22ISBT Opens Applications for the I TRY IT Programme 2027
-
Nov 9, 2026, 10:08Ibrahim Mansoor: Rare Tests, Common Diseases – Rethinking Autoimmune Diagnostics
-
Nov 9, 2026, 09:29Veronica Sanchez: A Framework for Woman’s Health
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services